Page last updated: 2024-12-05

2-picoline

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

2-Picoline, also known as 2-methylpyridine, is a colorless, flammable liquid with a pungent odor. It is a heterocyclic aromatic compound, belonging to the pyridine family. It is commonly produced as a by-product in the coal tar industry and can also be synthesized through various methods, including the Chichibabin reaction and the Hantzsch synthesis. 2-picoline finds applications as a precursor in the synthesis of pesticides, pharmaceuticals, and dyes. It also serves as a solvent and a reagent in various chemical reactions. Its importance stems from its versatile chemical properties and its ability to participate in a wide range of chemical transformations. Research on 2-picoline focuses on its synthesis, purification, and applications in various fields. Studies also investigate its environmental impact, its potential toxicity, and its role in biological systems. 2-picoline has been found to exhibit antifungal and antibacterial properties, making it an area of interest for developing novel antimicrobial agents. '

2-picoline: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

2-methylpyridine : A methylpyridine carrying a methyl substituent at position 2. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID7975
CHEMBL ID15732
CHEBI ID50415
MeSH IDM0523973

Synonyms (76)

Synonym
BIDD:ER0295
1333-41-1
pyridine, methyl-
nsc3409
.alpha.-methylpyridine
2-picoline
nsc-3409
o-picoline
picoline, alpha
109-06-8
2-methylpyridine
pyridine, 2-methyl-
.alpha.-picoline
wln: t6nj b1
picoline
CHEBI:50415 ,
alpha-picoline
o-methylpyridine
2-mepy
rcra waste no. u191
rcra waste number u191
nsc 3409
ccris 1721
ai3-24109
hsdb 101
einecs 203-643-7
ai3-2409
alpha-methylpyridine
2-methyl-pyridine
inchi=1/c6h7n/c1-6-4-2-3-5-7-6/h2-5h,1h
NCGC00160644-01
2-methylpyridine, 98%
NCIOPEN2_007919
NCIOPEN2_007826
CHEMBL15732
P0415
AKOS000119190
NCGC00160644-02
methylpyridine
o-picoline [un2313] [flammable liquid]
ec 203-643-7
3716q16q6a ,
unii-3716q16q6a
cas-109-06-8
dtxsid9021899 ,
tox21_111951
tox21_201693
dtxcid001899
NCGC00259242-01
FT-0613358
2-methylpyridine [hsdb]
.alpha.-picoline [mi]
amprolium hydrochloride impurity a [ep impurity]
STL268873
AM81276
alpha picoline
a-picoline
2-methylpridine
2--picoline
2-methyl pyridine
10259-19-5
picoline, .alpha.
J-510091
2-picoline, analytical standard
2-methylpyridine, lonza quality, >=99.0% (gc)
F0001-0192
2-picoline, 98%
mfcd00006332
2-picoline,(s);2-methylpyridine
Q2216745
2-methylpyridine pound>>o-picoline pound>>pyridine, 2-methyl-
BCP26524
methyl pyridine
EN300-19108
pyridine-2,3,4,5-d4,6-(methyl-d3)-
Z104472800

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
methylpyridine
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (15)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency0.47150.000214.376460.0339AID720691
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency52.43910.003041.611522,387.1992AID1159552; AID1159555
estrogen nuclear receptor alphaHomo sapiens (human)Potency35.01540.000229.305416,493.5996AID743069; AID743075
potassium voltage-gated channel subfamily H member 2 isoform dHomo sapiens (human)Potency35.48130.01789.637444.6684AID588834
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Neuronal acetylcholine receptor subunit alpha-3Rattus norvegicus (Norway rat)Kd64,000.00000.00000.00010.0003AID30392
Neuronal acetylcholine receptor subunit alpha-4Rattus norvegicus (Norway rat)Kd64,000.00000.00000.00010.0001AID30392
Neuronal acetylcholine receptor subunit alpha-2Rattus norvegicus (Norway rat)Kd64,000.00000.00000.00010.0001AID30392
Neuronal acetylcholine receptor subunit beta-2Rattus norvegicus (Norway rat)Kd64,000.00000.00000.00000.0001AID30392
Neuronal acetylcholine receptor subunit beta-3Rattus norvegicus (Norway rat)Kd64,000.00000.00010.00010.0001AID30392
Neuronal acetylcholine receptor subunit beta-4Rattus norvegicus (Norway rat)Kd64,000.00000.00010.00010.0003AID30392
Neuronal acetylcholine receptor subunit alpha-5Rattus norvegicus (Norway rat)Kd64,000.00000.00010.00010.0001AID30392
Neuronal acetylcholine receptor subunit alpha-6Rattus norvegicus (Norway rat)Kd64,000.00000.00010.00010.0001AID30392
Neuronal acetylcholine receptor subunit alpha-9Rattus norvegicus (Norway rat)Kd64,000.00000.00010.00010.0001AID30392
Neuronal acetylcholine receptor subunit alpha-7Rattus norvegicus (Norway rat)Kd64,000.00000.00010.00010.0001AID30392
Neuronal acetylcholine receptor subunit alpha-10Rattus norvegicus (Norway rat)Kd64,000.00000.00010.00010.0001AID30392
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Ceullar Components (1)

Processvia Protein(s)Taxonomy
plasma membraneNeuronal acetylcholine receptor subunit alpha-9Rattus norvegicus (Norway rat)
plasma membraneNeuronal acetylcholine receptor subunit alpha-10Rattus norvegicus (Norway rat)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (14)

Assay IDTitleYearJournalArticle
AID213129Inhibition of Thromboxane synthetase at 100 uM1981Journal of medicinal chemistry, Oct, Volume: 24, Issue:10
Highly selective inhibitors of thromboxane synthetase. 2. Pyridine derivatives.
AID1134914Dissociation constant, pKa of the compound1979Journal of medicinal chemistry, Sep, Volume: 22, Issue:9
Lysosomotropic agents. 1. Synthesis and cytotoxic action of lysosomotropic detergents.
AID30377Maximum percent of enhancement of binding.1985Journal of medicinal chemistry, Sep, Volume: 28, Issue:9
Structure-activity relationships of some pyridine, piperidine, and pyrrolidine analogues for enhancing and inhibiting the binding of (+/-)-[3H]nicotine to the rat brain P2 preparation.
AID30392Compounds was evaluated for ability to enhance the binding of (+/-)-[3H]nicotine to the rat brain P2 fraction at binding site 41985Journal of medicinal chemistry, Sep, Volume: 28, Issue:9
Structure-activity relationships of some pyridine, piperidine, and pyrrolidine analogues for enhancing and inhibiting the binding of (+/-)-[3H]nicotine to the rat brain P2 preparation.
AID1149238Dissociation constant, pKa of the compound1976Journal of medicinal chemistry, Apr, Volume: 19, Issue:4
Mode of action and quantitative structure-activity correlations of tuberculostatic drugs of the isonicotinic acid hydrazide type.
AID30389Ability to enhance the binding of (+/-)-[3H]nicotine to the rat brain P2 fraction at binding site 21985Journal of medicinal chemistry, Sep, Volume: 28, Issue:9
Structure-activity relationships of some pyridine, piperidine, and pyrrolidine analogues for enhancing and inhibiting the binding of (+/-)-[3H]nicotine to the rat brain P2 preparation.
AID30387Compound was evaluated for ability to enhance the binding of (+/-)-[3H]nicotine to the rat brain P2 fraction at binding site 1; 10e-10-10e-41985Journal of medicinal chemistry, Sep, Volume: 28, Issue:9
Structure-activity relationships of some pyridine, piperidine, and pyrrolidine analogues for enhancing and inhibiting the binding of (+/-)-[3H]nicotine to the rat brain P2 preparation.
AID30378Maximum percent of inhibition of binding was determined1985Journal of medicinal chemistry, Sep, Volume: 28, Issue:9
Structure-activity relationships of some pyridine, piperidine, and pyrrolidine analogues for enhancing and inhibiting the binding of (+/-)-[3H]nicotine to the rat brain P2 preparation.
AID30517Compounds was evaluate for their ability to enhance (+/-)-[3H]nicotine binding and mean enhancement of binding at a dose range 10 E -10 - 10 E -4 M was reported1985Journal of medicinal chemistry, Sep, Volume: 28, Issue:9
Structure-activity relationships of some pyridine, piperidine, and pyrrolidine analogues for enhancing and inhibiting the binding of (+/-)-[3H]nicotine to the rat brain P2 preparation.
AID30391Ability to enhance the binding of (+/-)-[3H]nicotine to the rat brain P2 fraction at binding site 3.1985Journal of medicinal chemistry, Sep, Volume: 28, Issue:9
Structure-activity relationships of some pyridine, piperidine, and pyrrolidine analogues for enhancing and inhibiting the binding of (+/-)-[3H]nicotine to the rat brain P2 preparation.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (32)

TimeframeStudies, This Drug (%)All Drugs %
pre-199011 (34.38)18.7374
1990's0 (0.00)18.2507
2000's4 (12.50)29.6817
2010's15 (46.88)24.3611
2020's2 (6.25)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 46.37

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index46.37 (24.57)
Research Supply Index3.53 (2.92)
Research Growth Index4.69 (4.65)
Search Engine Demand Index67.75 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (46.37)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other33 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]